https://scholars.lib.ntu.edu.tw/handle/123456789/520069
標題: | Discontinuation of statin therapy associates with Parkinson disease: A population-based study | 作者: | Yen-Chieh Lee CHIN-HSIEN LIN RUEY-MEEI WU Min-Shung Lin JOU-WEI LIN CHIA-HSUIN CHANG Mei-Shu Lai |
公開日期: | 2013 | 卷: | 81 | 期: | 5 | 起(迄)頁: | 410-416 | 來源出版物: | Neurology | 摘要: | Objective: To evaluate the effect of discontinuing statin therapy on incidence of Parkinson disease (PD) in statin users. Methods: Participants who were free of PD and initiated statin therapy were recruited between 2001 and 2008. We examined the association between discontinuing use of statins with different lipophilicity and the incidence of PD using the Cox regression model with time-varying statin use. Results: Among the 43,810 statin initiators, the incidence rate for PD was 1.68 and 3.52 per 1,000,000 person-days for lipophilic and hydrophilic statins, respectively. Continuation of lipophilic statins was associated with a decreased risk of PD (hazard ratio [HR] 0.42 [95%confidence interval 0.27-0.64]) as compared with statin discontinuation, which was not modified by comorbidities or medications. There was no association between hydrophilic statins and occurrence of PD. Among lipophilic statins, a significant association was observed for simvastatin (HR 0.23 [0.07-0.73]) and atorvastatin (HR 0.33 [0.17-0.65]), especially in female users (HR 0.11 [0.02-0.80] for simvastatin; HR 0.24 [0.09-0.64] for atorvastatin). As for atorvastatin users, the beneficial effect was seen in the elderly subgroup (HR 0.42 [0.21-0.87]). However, long-term use of statins, either lipophilic or hydrophilic, was not significantly associated with PD in a dose/duration- response relation. Conclusions: Continuation of lipophilic statin therapy was associated with a decreased incidence of PD as compared to discontinuation in statin users, especially in subgroups of women and elderly. Long-term follow-up study is needed to clarify the potential beneficial role of lipophilic statins in PD. ? 2013 American Academy of Neurology. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84881309914&doi=10.1212%2fWNL.0b013e31829d873c&partnerID=40&md5=8613f9feacc341c2da7d6e68d83adfd8 https://scholars.lib.ntu.edu.tw/handle/123456789/520069 |
ISSN: | 0028-3878 | DOI: | 10.1212/WNL.0b013e31829d873c | SDG/關鍵字: | antiarrhythmic agent; anticonvulsive agent; antidepressant agent; antihypertensive agent; antithrombocytic agent; atorvastatin; beta adrenergic receptor blocking agent; diuretic agent; fluindostatin; mevinolin; neuroleptic agent; nitrate; nonsteroid antiinflammatory agent; pravastatin; rosuvastatin; simvastatin; adult; aged; article; comorbidity; diabetes mellitus; drug withdrawal; female; groups by age and sex; human; incidence; lipophilicity; major clinical study; male; Parkinson disease; prescription; priority journal; risk assessment; risk benefit analysis; treatment withdrawal; Aged; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Population Surveillance |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。